Cargando…

Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials

Platinum (Pt)-based chemo-regimens have been proved effective in neoadjuvant and salvage chemotherapy of triple negative breast cancer (TNBC). However, the survival benefit of Pt-based regimens in early stage TNBC(eTNBC) treatment has remained unclear. We conducted a meta-analysis to explore its rol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bian, Lei, Yu, Ping, Wen, Jiahuai, Li, Na, Huang, Wanwei, Xie, Xiaoming, Ye, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692362/ https://www.ncbi.nlm.nih.gov/pubmed/34934050 http://dx.doi.org/10.1038/s41523-021-00367-w

Ejemplares similares

Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials
por: Ye, Feng, et al.
Publicado: (2022)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens
por: Chen, Chien-An, et al.
Publicado: (2018)

Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
por: Kim, Hyun-Ah, et al.
Publicado: (2015)

Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials
por: Xie, Kaigang, et al.
Publicado: (2022)

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression
por: KHALAF, DANIEL, et al.
Publicado: (2014)

Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis
por: Ghafouri, Sanaz N., et al.
Publicado: (2022)

A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients
por: Wang, Biyun, et al.
Publicado: (2022)

The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer
por: Biswas, Tithi, et al.
Publicado: (2017)

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer
por: Duan, Fangfang, et al.
Publicado: (2022)

Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
por: Lin, Canling, et al.
Publicado: (2022)

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
por: Lips, Esther H., et al.
Publicado: (2020)

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
por: de Boo, Leonora W., et al.
Publicado: (2022)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer
por: Hsu, Ju-Yi, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Advances in the Management of Early-Stage Triple-Negative Breast Cancer
por: Bhardwaj, Prarthna V., et al.
Publicado: (2023)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence
por: Holanek, Milos, et al.
Publicado: (2021)

Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer
por: Chen, Yi-Yu, et al.
Publicado: (2020)

Radiotherapy after surgery has significant survival benefits for patients with triple‐negative breast cancer
por: Yao, Yi, et al.
Publicado: (2019)

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2023)

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
por: He, Qin, et al.
Publicado: (2021)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis
por: Cortes, Javier, et al.
Publicado: (2023)

Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database
por: Zhang, Yuyuan, et al.
Publicado: (2023)

Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis
por: Zhang, Liulu, et al.
Publicado: (2022)

Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer
por: Srimuninnimit, Vichien, et al.
Publicado: (2018)

Survival benefit of surgery with radiotherapy vs surgery alone to patients with T2-3N0M0 stage esophageal adenocarcinoma
por: Song, Yaqi, et al.
Publicado: (2016)

Comparison of the expression levels of lysine-specific demethylase 1 and survival outcomes between triple-negative and non-triple-negative breast cancer
por: Zhao, Kangrong, et al.
Publicado: (2021)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer
por: Celik, Alan, et al.
Publicado: (2023)

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
por: Loi, Sherene, et al.
Publicado: (2022)

The relationship between immediate postmastectomy reconstruction modalities and survival benefits in patients with triple negative breast cancer
por: Dai, Luyao, et al.
Publicado: (2022)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

Is breast conservation superior to mastectomy in early stage triple negative breast cancer?
por: Saifi, Omran, et al.
Publicado: (2022)

The Functional Impact of Alternative Splicing on the Survival Prognosis of Triple-Negative Breast Cancer
por: Wu, Sijia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k68vtro6o0eh49i47fa85m7oug